Onyx Pharmaceuticals (ONXX +2%) could command at least $70/share in a potential sale, or...

|By:, SA News Editor

Onyx Pharmaceuticals (ONXX +2%) could command at least $70/share in a potential sale, or 70%-plus above its average in the past 20 days - pricey but perhaps still of interest to firms facing patent expirations such as Pfizer (PFE), Bloomberg says. Onyx is developing a drug to treat blood cancer, and cancer is a hot area for drugmakers in the market for transactions and new drugs.